GO
Loading...

Medicine

More

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • AstraZeneca cancer drug, companion test approved Friday, 19 Dec 2014 | 1:24 PM ET

    TRENTON, N.J.— U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The Food and Drug Administration also approved a companion diagnostic test from Myriad Genetics Inc. of Salt Lake City called BRACAnalysis CDx. Richard Pazdur, director of the...

  • Juno Therapeutics soars in Nasdaq debut Friday, 19 Dec 2014 | 12:13 PM ET

    CEO Hans Bishop told CNBC investors are feeling optimistic about immunotherapy and the company's cancer treatments in development.

  • Juno Therapeutics' stock surges in market debut Friday, 19 Dec 2014 | 11:51 AM ET

    NEW YORK— Shares of cancer treatment company Juno Therapeutics Inc. jumped 46 percent in their stock market debut Friday. The Seattle- based company raised $264.5 million after selling more than 11 million shares at $24 per share. The stock rose $11 to close at $35, after rising as high as $39.50 earlier.

  • Juno CEO: Developing new hope for cancer  Friday, 19 Dec 2014 | 10:43 AM ET

    "We're trying to develop treatments that offer new hope or patients battling cancer," says Hans Bishop, Juno Therapeutics CEO, explaining the technology behind Juno.

  • Dec 19- European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade. The drug, sold as Contrave by partner Takeda Pharmaceutical Co in the United States, will be marketed as Mysimba in Europe. The third obesity...

  • Ahead of the Bell: ImmunoGen shares tumble Friday, 19 Dec 2014 | 8:14 AM ET

    ImmunoGen CEO Daniel Junius said that the company was disappointed, but he also noted that Roche has several other Kadcyla studies underway, including one related to gastric cancer. The study results won't affect the company's 2015 guidance or the approved use of Kadcyla, according to ImmunoGen Inc.. Shares of the Waltham, Massachusetts, company tumbled $4.05,...

  • Dec 19- Orexigen Therapeutics Inc said European regulators recommended the approval of the drugmaker's obesity pill on Friday. The European Commission is expected to give its decision on the drug in early 2015, the company said. The drug, Mysimba, is already sold as Contrave in the United States by Orexigen's partner Takeda Pharmaceutical Co..

  • *Ending Phase III trial with Alzheimer's drug gantenerumab. ZURICH/ LONDON, Dec 19- Roche said on Friday it would discontinue a late-stage study of an experimental Alzheimer's drug after it failed to prove effective, underlying the difficulty of treating the memory-robbing disease. Alzheimer's, the most common form of dementia, already afflicts 44 million...

  • Correction: Meningitis Outbreak story Thursday, 18 Dec 2014 | 2:46 PM ET

    BOSTON— In a story Dec. 17 about arrests in a deadly meningitis outbreak, The Associated Press erroneously reported Stuart Delery's title. BOSTON— Mold and bacteria were in the air and on workers' gloved fingertips. Federal prosecutors leveled those allegations in bringing charges Wednesday against 14 former owners or employees of a Massachusetts pharmacy in...

  • Merck buys Swiss biotech with promising cancer drug Thursday, 18 Dec 2014 | 12:16 PM ET

    KENILWORTH, N.J.— Drugmaker Merck says it's bought a Swiss biotech company developing cancer drugs as part of its strategy to be a top player in cancer, one of the hottest pharmaceutical research areas. Merck& Co., based in Kenilworth, New Jersey, will pay up to $110 million upfront to OncoEthix. The privately held company could receive further payments of up to $265...

  • A fresh setback for efforts to cure HIV infection Thursday, 18 Dec 2014 | 7:53 AM ET

    So far, Timothy Ray Brown, a U.S. man treated in Germany, remains the only person thought to have been cured of infection with HIV, the virus that causes AIDS. Gero Huetter of the University of Berlin. In a research letter in Thursday's New England Journal of Medicine, Huetter tells of six other patients with HIV and various blood cancers who received similar...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Obesity can be deemed a disability at work: EU Thursday, 18 Dec 2014 | 7:00 AM ET

    Europe's top court ruled that obese people can be considered as disabled, meaning they would be covered by an EU law barring discrimination at work.

  • European court rules obesity can be a disability Thursday, 18 Dec 2014 | 6:43 AM ET

    LONDON— Obesity can be a disability, the European Court of Justice ruled Thursday— a decision that could have widespread consequences across the 28- nation bloc for the way in which employers deal with severely overweight staff. According to Jacob Sand, Kaltoft's lawyer, the ruling means employers will have an "active obligation" to cater to the needs of their...

  • Study: Removing clot helps limit stroke disability Wednesday, 17 Dec 2014 | 2:02 PM ET

    For the first time in two decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a standard clot-busting medicine lowered the risk that a stroke sufferer would end up seriously disabled. In fact, three studies published last year in the...

  • Bird flu found in wild birds in Washington state - USDA Wednesday, 17 Dec 2014 | 12:18 PM ET

    Dec 17- Two strains of avian influenza have been confirmed in wild birds in Washington state, near the U.S. border with Canada, but there is no immediate cause for public health concerns, U.S. agriculture officials said on Wednesday. The other strain, H5N8, was found in captive gyrfalcons that were fed hunter-killed wild birds, the USDA said. Neither virus has been...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • EXCLUSIVE-Amgen leukemia drug to carry $178,000 price tag Wednesday, 17 Dec 2014 | 11:28 AM ET

    Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available this month, which would make it one of the world's most expensive cancer drugs. Company spokeswoman Danielle Bertrand said the price for the infused medicine, called Blincyto, would reflect two courses of treatment, at...

  • Dec 16- Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. The company said it was also...